As mentioned earlier, the most important effect of incretins is to stimulate the production and secretion of insulin by the pancreas, and clinical studies show that the activation of this process, whether by stimulation of GLP-1 by semaglutide alone or simultaneous stimulation of GLP-1/GIP by tirzepatide, is associated with better glycemic control in type 2 diabetics
One study explained: Out of all, the most potent DPP-IV inhibitors were found to be resveratrol, luteolin, apigenin and flavone having activity in nanomolar range.[ref] Related article: Resveratrol: Genetics and Bioavailability Diets that increase GLP-1:[ref] Olive oil: Researchers have found that in addition to glucose, long-chain fatty acids also stimulate GLP-1 secretion in the small intestines
Listen to it and drink up
Higher attained dose during the pre-landmark period was associated with lower post-landmark cardiovascular risk Patients who reached high-dose semaglutide during the pre-landmark period (1.7 mg
Studies show semaglutide produces significant reductions in visceral fat, often disproportionate to total weight loss
